# Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

> **NCT04541173** · PHASE2 · TERMINATED · sponsor: **Aiwu Ruth He, MD** · enrollment: 6 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **OTHER:** Y-90 TARE
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04541173
- **Lead sponsor:** Aiwu Ruth He, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-30
- **Primary completion:** 2023-06-18
- **Final completion:** 2023-06-30
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Due to slow accrual.
- **Last updated:** 2024-06-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04541173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04541173, "Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT04541173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*